Characterization of single-nucleotide polymorphisms implicated in the pathogenesis of Crohn's disease by Whitley, Julia
ABSTRACT 
 The inflammatory bowel diseases (IBD) are a group of chronic inflammatory conditions 
involving the gastrointestinal tract. IBD affects between 1 and 2 million Americans, and its 
incidence is increasing for unknown reasons. One of the predominant forms of IBD is Crohn’s 
disease (CD). Genome-wide association studies (GWAS) have linked many single-nucleotide 
polymorphisms (SNPs) within genes of the immune system to CD pathogenesis, but it is 
unknown which of these SNPs are causative. In genetically susceptible individuals, CD can 
result from a disruption in the balance between pro-inflammatory and anti-inflammatory gene 
expression in intestinal immune cells. Gene expression is partially regulated by the binding of 
transcription factors to DNA to either activate or repress target genes. The ability of transcription 
factors to bind to DNA may be influenced by chromatin accessibility. To determine the location 
of accessible, or “open” chromatin regions in the genome, we used Formaldehyde-Assisted 
Isolation of Regulatory Elements (FAIRE). Many of these open chromatin regions were located 
near genes involved in immune system function. A subset of these open chromatin regions 
overlapped with CD-associated SNPs. I used luciferase reporter assays to determine the potential 
regulatory function of a CD-linked SNP found in a region of open chromatin. Understanding the 
function of disease-associated genetic variants will elucidate the importance of genetic 
susceptibility in CD pathogenesis. 
INTRODUCTION 
Inflammatory bowel disease (IBD) 
 The inflammatory bowel diseases (IBD) are a broad group of conditions that involve 
chronic or recurring inflammation of the gastrointestinal tract. While most cases can be managed 
with medication, there is no cure for IBD, making its increasing prevalence a major public health 
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concern. The two major forms of IBD are Crohn’s disease (CD) and ulcerative colitis. While the 
symptoms of these two conditions are similar, they are distinct illnesses that affect different areas 
of the gastrointestinal tract. Crohn’s disease (CD) may affect any part of the gastrointestinal 
tract, while ulcerative colitis (UC) is limited to the lining of the colon and rectum. In genetically 
susceptible individuals, IBD is caused by an inappropriate immune response to the enteric 
microbiota that leads to intestinal inflammation. The hyper-activation of immune cells, as 
demonstrated by increased production of pro-inflammatory cytokines or decreased production of 
anti-inflammatory cytokines, is a central event in the development of CD[Dionne,Rogler]. The 
increasing incidence of CD in developed nations, including the United States, suggests that 
environmental triggers may interact with genetic factors to contribute to the development of this 
disease[Dixon, Molodecky]. 
Genetic variation associated with Crohn’s disease 
 Genome-wide association studies (GWAS) and subsequent meta-analyses have linked a 
total of 163 single-nucleotide polymorphisms (SNPs) to IBD[Jostins]. Most of these loci are 
associated with both Crohn’s disease and ulcerative colitis and are found in genes of the immune 
system, specifically genes predominantly expressed in intestinal macrophages. A unique 
characteristic of these GWAS findings is the observation that the majority of identified CD-
associated variants occur in regions of the genome that do not code for proteins[Mirza]. Non-
coding regions of the genome often act as regulatory elements that influence gene expression, 
such as promoters that increase the transcription of proximal downstream genes or repressors 
that serve to downregulate gene expression. In order to influence gene expression, regulatory 
elements must be accessible to transcription factors. However, the default state of chromatin is a 
“closed” conformation characterized by tight coiling of DNA around histone proteins. In 
	   3 
contrast, histone-free “open” chromatin regions can be readily accessed by transcription factors. 
Regulatory elements are thus most often found in regions of open chromatin that may be 
accessed by transcription factors and subsequently influence the expression of either nearby or 
distant genes[Simon]. 
Open chromatin regions associated with Crohn’s disease 
 Formaldehyde-Assisted Isolation of Regulatory Elements (FAIRE-seq) is a technique 
used to identify regions of open chromatin throughout the genome indicative of potential 
regulatory elements. Peaks representing open chromatin identified by FAIRE are consistently 
found within known regulatory regions, including transcription start sites (TSS) and 
enhancers[Simon]. Additional methods to identify open chromatin, including DNase-seq, have 
been performed on samples obtained from genotyped CD patients; these previous studies 
indicate that CD-associated SNPs identified by GWAS often occur in regions of open 
chromatin[Maurano]. We therefore hypothesize that causative CD-associated SNPs occur in 
gene regulatory elements and can be identified using FAIRE-seq as changes in chromatin 
organization, leading to more accessible chromatin that can be readily accessed by transcription 
factors and influence gene expression. In response to environmental cues such as the enteric 
microbiota, these SNPs may directly mediate chronic intestinal inflammation through the 
transcriptional regulation of gene products, such as pro- and anti-inflammatory cytokines. 
Testing the potential regulatory function of CD-associated SNPs 
In the present study, I tested the potential regulatory function of a CD-associated SNP 
identified by GWAS: rs10896788. Our genotype and FAIRE-seq data previously obtained from 
uninflamed resected colon tissue from CD patients reveal that many CD-associated SNPs overlap 
with open chromatin regions identified by FAIRE, suggesting that these SNPs occur in regions 
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of open chromatin. One of these SNPs is rs1089677, which occurs at position q12.1 on 
chromosome 11. Luciferase reporter-based cell assays were used to study the potential regulatory 
function of the region containing this SNP. These assays measure the effect of a regulatory 
element on the transcription of a reporter gene (LUC) whose product catalyzes a bioluminescent 
reaction. In the general protocol for this assay, a SNP is inserted into the multiple cloning site of 
an expression vector (pGL4.23). Transformation of the plasmid containing the DNA insert into 
DH5α E.coli cells followed by heat shock allows the vector to be incorporated into the bacterial 
genome. Transfection of the replicated insert as well as a Renilla vector that constitutively 
transcribes luciferase into cells provides an internal control. Subsequent measurement of 
luminosity reveals the effect of the DNA variant on gene expression normalized to Renilla. 
The aim of this study was to identify the effect of the rs10896788 variant on gene 
expression and determine its potential role in gene regulation and disease etiology. 
Understanding the function of disease-associated SNPs identified by GWAS is important as 
genetic factors are increasingly found to play a role in the development of CD and other chronic 
illnesses. Identifying SNPs that upregulate or downregulate the expression of coding sequences 
in the genome implies that when induced into a nucleosome-free state, these regulatory regions 
may increase the synthesis of pro-inflammatory cytokines or decrease the synthesis of anti-
inflammatory cytokines. The potential for future screening efforts and targeted therapies for CD 
will depend on an understanding of the function of genetic variants in health and disease. 
MATERIALS AND METHODS 
Selection of SNP for functional study 
 The variant rs10896788 was chosen for functional study due to both its association with 
CD by GWAS and location in a nucleosome-free region in the genome, as identified by a 
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previous FAIRE-seq experiment performed on uninflamed resected colon tissue from CD 
patients recruited at UNC Hospitals. To identify the presence of this SNP in CD patients, SNP 
genotyping was performed at the UNC Genomics Core on uninflamed resected colon tissue 
obtained from these CD patients. A sample ID of 42200 was given to the patient homozygous for 
the disease-associated SNP (G). A sample ID of 44000 was given to the patient homozygous for 
the non-risk allele (A) which served as a negative control.  
Table 1. Correlation between genotype and FAIRE-identified open chromatin regions. 
Patient ID Genotype RPKM FAIRE signal 
40500 2 5.773738 48 
40700 1 2.895777 65 
41300 2 9.680131 84 
42200 2 5.257381 47 
43100 1 13.65219 63 
43300 2 1.301694 88 
44000 0 2.064365 No peak 
45000 1 5.065185 42 
Table 1. Presence of rs10896788 correlates with more open chromatin. Genotype 0: 0 copies 
of SNP of interest (rs10896788); Genotype 1: 1 copy of SNP; Genotype 2: 2 copies of SNP. 
RNA-seq reads per kilobase per million (RPKM) corresponds to levels of LPXN expression 
associated with each genotype. Higher values for FAIRE signal correspond to more open 
chromatin at the location of the SNP. Genotype, FAIRE, and RNA-seq data were collected by 
Adam Robinson and Chelsea Raulerson. 
 
In Table 1, RNA-seq reads per kilobase per million (RPKM) values reflect expression values of 
the gene closest to this locus in hg19, LPXN. Patient 44000 lacked a FAIRE signal at the location 
of the SNP and demonstrated a lower RPKM value (2.064365), suggesting that the default state 
of chromatin at this locus with two non-risk alleles is closed with lower levels of LPXN 
	   6 
expression. In contrast, patient 42200 and other patients who possessed two copies of the SNP 
demonstrated a relatively high FAIRE signal at this locus with two copies of the SNP, and a 
higher RPKM value (5.257381) indicative of higher levels of LPXN expression. DNA from 
patient 42200 was chosen for use in luciferase assays over the DNA from the other patients that 
possessed two copies of the SNP due to the fact that more DNA was available from this patient. 




Figure 1. FAIRE-seq demonstrates a difference in open chromatin signal. FAIRE peaks 
shown in red correspond to regions of open chromatin. Patient 44000, with both non-risk alleles, 
lacks the FAIRE peak indicative of open chromatin at the location of rs10896788 on chromsome 
11 (outlined in black). Patient 42200, with two copies of this SNP, demonstrates a FAIRE peak 
at this locus. FAIRE-seq data and the resulting figure were produced by Matt Weiser. 
 
Cell culture 
 In preparation for the transfection, one adherent hepatocellular carcinoma cell line, 
human-derived HepG2, was maintained at 37oC with 5% CO2. The cells were cultured in 1X 
MEM-alpha (Gibco®, Life Technologies) with 1 mM sodium pyruvate supplemented with 10% 
FBS. The medium was discarded and replaced every 2-3 days. 
Preparation of DNA sequence containing SNP for cloning 
 The DNA sequence (~200 base pairs) surrounding rs10896788 from both patient 42200 
and patient 44000 was amplified by PCR using designed primers 30 base pairs in length that 
contained restriction sites for Kpn1 and Xho1. The primers were reconstituted to 100 µM in 
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sterile H2O. A gradient PCR was run to select the best annealing temperature for amplification of 
the desired fragments. After optimizing the annealing temperature, PCR was run on the patients’ 
DNA samples. A 1.5% agarose gel was then run using the amplified samples. The bands 
containing the remaining PCR product were then cut from the gel and proceeded to gel 
purification using the Promega Wizard SV Gel and PCR CleanUp System (Cat# A9282). The 
purified products were resuspended in 30 µL of sterile H2O and the concentration of DNA 
remaining in each sample was read using a NanoDropTM. The amplified sequences and enhancer-
specific vector (pGL4.23) were then digested in separate tubes with the restriction enzymes 
Kpn1 and Xho1 and incubated at 37oC for 4 hours to make the desired sequences and vector 
compatible for cloning. The restricted products were then purified using the Promega Wizard SV 
Gel and PCR CleanUp System (Cat# A9282), and the concentration of the purified products was 
read using a NanoDropTM. To ligate the digested insert and vector, 100 ng of vector and 65 ng of 
insert were incubated at room temperature for 2 hours with T4 ligase (Thermo Scientific). The 
ligated sample was then heated at 65oC for 10 minutes to inactivate the T4 ligase. To produce 
thousands of copies of the ligated vector and insert, the ligation mixture was added to MAX 
Efficiency® DH5αTM Competent Cells (Invitrogen 18258012). The plasmid cloning vector 
pUC19 (Invitrogen) was used as an internal control. The bacterial cells were incubated on ice for 
20 minutes and then underwent heat shock at 42oC for 55 seconds. The cells were then incubated 
on ice for 5 minutes before adding 250 µL S.O.C. medium and shaking at 37oC for 1 hour. The 
cells containing the plasmid were then spread on agar plates and incubated at 37oC for 24 hours. 
The next day, 3 colonies were picked from each plate and added to 14 mL tubes containing 5 mL 
of LB broth with ampicillin. The tubes were shaken for 20 hours at 37oC. A QIAGEN MiniPrep 
Kit was then used to extract DNA from the colonies, and the plasmid concentration was 
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measured using a NanoDropTM. A diagnostic restriction test was then performed to ensure that 
the plasmids contained the insert containing the SNP. Plasmid DNA was digested with Kpn1 and 
Xho1 and incubated at 37oC for 2 hours. A 1% agarose gel was then run to test for inserts in each 
restricted sample. Samples that produced a band at the expected location of the insert (~200 base 
pairs) were sequenced at the UNC Genome Analysis Facility. The sequences were analyzed 
using Sequencher® to ensure that the SNP was correct and that the insert did not contain any 
mutations. 
Transfection and luciferase reporter assays 
 To test the effect of rs10896788 on luciferase production in HepG2 cells, the SNP was 
cloned in the forward orientation into a minimal promoter-containing firefly luciferase vector 
pGL4.23 (Promega, Madison, WI). The plasmids for both alleles (G and A) were transfected in 
duplicate (~700 ng/well) into the HepG2 cell line. Approximately 70,000 cells per well were 
transfected with both luciferase constructs and the Renilla-luciferase control vector using 
Lipofectamine® 2000 in a 24-cell plate. Cells were assayed 48 hours after transfection using the 
Dual Luciferase Assay (Promega). The plates were then read using a luminometer with 
Luciferase Assay Reagent and Stop and Glo Buffer in separate injectors. A two-sided t-test was 
used to compare luciferase activity and normalize the values to Renilla luciferase activity. 
RESULTS 
Optimal annealing temperature determined for PCR 
 A gradient PCR was run on DNA that was not obtained from patients 42200 and 44000 at 
six different annealing temperatures, using both the forward and reverse primers at each 
temperature. A 1% agarose gel was then run to identify at which temperature the greatest 
concentration of DNA appeared on the imaged gel (Fig. 2). Based on the fact that the brightest 
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bands for both the forward and reverse orientations appeared at 62oC, this was the temperature 














Figure 2. Nucleic acid gel obtained for gradient PCR performed on junk DNA. Forward and 
reverse primer products are represented by F and R, respectively. A 100 base-pair ladder was 
used to confirm the size of the PCR products (~200 base pairs). 
 
Potential enhancer-specific activity of rs10896788 
Each plasmid was transfected into HepG2 cells in duplicate with three separate plasmids 
for each allele: the Renilla plasmid, the plasmid containing the rs10896788 SNP (positive 
control), and the plasmid containing the non-risk allele (negative control). Relative LUC 
expression normalized to the empty vector (Renilla control) was read using a luminometer. 
GraphPad Prism® analysis indicated that the plasmid containing the risk allele (G) increased 
LUC transcription compared to the control allele (A) (Fig. 3). However, it is inconclusive from 
this analysis whether rs10896788 increases overall LUC transcription in HepG2 cells. 







  53oC     55oC       58oC    60oC    62oC    65oC 
F    R    F    R     F    R    F    R    F    R    F    R             
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Figure 3. rs10896788 alleles exhibit differential transcriptional activity in pGL4.23. 
Enhancer activity in the forward orientation with respect to LUC was studied in HepG2 cells 
with the CD-associated allele (G) and the non-risk allele (A). Statistically significant allele-
specific enhancer activity was observed. The risk allele G displays greater transcriptional activity 
in the forward orientation than the non-risk allele A with respect to LUC in a minimal promoter 
vector (pgL4.23). Error bars represent SD of 5 independent clones for each allele. Results are 
expressed as a fold change normalized to the empty vector control. P value was calculated using 
a two-sided t-test. P = 1.9 × 10-3. 
 
Evidence that rs10896788 does not function as a promoter 
The cloning protocol was repeated using a basic vector not containing a promoter region 
(pGL4.10) instead of the minimal promoter vector designed to confirm enhancer-specific activity 
(pGL4.23). Each plasmid was again transfected into HepG2 cells in duplicate with three separate 
plasmids for each allele: the Renilla plasmid, the plasmid containing the risk allele (G), and the 
plasmid containing the non-risk allele (A). Relative LUC expression normalized to the empty 
vector (Renilla control) was read using a luminometer. GraphPad Prism® analysis indicated that 
the plasmid containing the risk allele (G) demonstrated similar LUC transcription compared to 
the control allele (A). However, these results were not statistically significant and the error bars 
displayed significant overlap (Fig.4). 
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Figure 4. rs10896788 alleles exhibit similar transcriptional activity in pGL4.10. Promoter 
activity in the forward orientation with respect to LUC was studied in HepG2 cells with the CD-
associated allele (G) and the non-risk allele (A). No significant difference in transcriptional 
activity was observed with respect to LUC in a basic vector lacking a promoter (pgL4.10). Error 
bars represent SD of 5 independent clones for each allele. Results are expressed as a fold change 
normalized to the empty vector control. P >> 0.05. 
 
Upon examining the values read for the Renilla vector by the luminometer, it was 
discovered that the empty vector yielded higher values for LUC expression than the Renilla 
vector. This finding is inconsistent with the fact that the empty vector should yield similar LUC 
expression values as the Renilla vector, as neither contain a regulatory element. Based on these 
considerations, the analysis was performed again by normalizing all luciferase readings from 
pGL4.10 to the average of the empty vector values. This analysis indicated that there was no 
significant difference in transcriptional activity between the risk allele (G) and non-risk allele 
(A), but the results were not statistically significant with widely overlapping error bars (Fig. 5). 
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Figure 5. rs10896788 alleles exhibit similar transcriptional activity in pGL4.10. Promoter 
activity in the forward orientation with respect to LUC was studied in HepG2 cells with the CD-
associated allele (G) and the non-risk allele (A). No significant difference in transcriptional 
activity was observed with respect to a basic vector with no promoter (pgL4.10). Error bars 
represent SD of 5 independent clones for each allele. Results are expressed as a fold change 
normalized to the empty vector control. P >> 0.05. 
 
DISCUSSION 
Here we show that the region containing the CD-associated SNP rs10896788 has a 
potential role as a regulatory element that may increase gene expression in liver cells. In the 
HepG2 cell line, this variant displayed an increase in gene expression compared to the non-risk 
allele when cloned into a minimal promoter vector (pGL4.23). We also show that this variant 
displayed no significant difference in transcriptional activity compared to the non-risk allele 
when cloned into a promoter-specific vector. These results suggest that the presence of the G 
allele at this locus may be associated with a change in chromatin accessibility, allowing this 
region to act as a regulatory element; specifically, it may act as an enhancer. 
Our hypothesis at the beginning of this study was that CD-associated SNPs found in 
regions of open chromatin may act as regulatory elements that contribute to CD pathogenesis by 
affecting the production of pro- or anti-inflammatory cytokines, contributing to the imbalance in 
	   13 
pro-and anti-inflammatory gene expression characteristic of the chronic inflammation found in 
CD. Confirming the fact that rs10896788 occurs in a region of open chromatin using FAIRE-seq, 
while the non-risk allele was associated with closed chromatin, was the first indication that this 
variant is associated with a change in chromatin organization. Our suggestion that this variant 
may affect gene expression was also supported by our observations using luciferase assays. 
Although preliminary, these results are significant in that they propose an alternative 
explanation for CD etiology that incorporates the role of genetic variation in the development 
and varying levels of severity of this chronic disease. When SNPs occur in protein-coding 
regions of the genome, their contribution to disease can be readily observed as changes in protein 
structure or function. For example, sickle cell anemia results from a mutation in a single gene 
that changes the conformation of hemoglobin. The fact that the majority of SNPs associated with 
CD occur in noncoding regions of the genome suggests that gene regulation and chromatin 
accessibility contribute to disease pathogenesis in a manner distinct from many other chronic 
illnesses[Natoli]. If it is found that certain genetic variants associated with CD have a regulatory 
function that serves to increase or decrease cytokine production, more targeted immunotherapies 
and genetic screening programs may be developed that can serve to personalize CD treatment. 
While our finding that the CD-associated allele at this locus increases LUC transcription 
relative to the non-risk allele is statistically significant, there are several alternative 
interpretations of these results that should be addressed. It cannot be concluded that rs10896788 
increases overall luciferase production, as the relative luciferase values were similar between the 
empty vector and positive control as determined using a two-sided t-test. To further investigate 
whether rs10896788 acts as an enhancer element, the reverse insertion will need to be tested in a 
similar luciferase assay, as only the forward insertion was tested here. Another consideration is 
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the fact that in the human genome, this locus occurs upstream of the LPXN gene. This gene 
encodes leupaxin, a protein preferentially expressed in hematopoietic cells. It cannot be 
concluded that rs10896788 increases LPXN transcription, as only tested LUC transcription was 
tested here. Further, RNA-seq reads per kilobase per million indicated relatively low levels of 
LPXN expression in intestinal tissue, even in the patient with both copies of the SNP (Table 1).  
In addition, our study contained several limitations due to the difficulty of replicating a sequence 
found in human cells into a luciferase reporter assay. Primarily, the HepG2 cell line used in these 
experiments are liver cells, while macrophages are the disease-relevant cell type in CD. 
To address these limitations and further elucidate the role of this potential variant in CD 
pathogenesis, future directions will involve transfection of this variant into the disease-relevant 
cell type, specifically a macrophage cell line. The effect of rs10896788 on transcriptional activity 
when transfected into a macrophage cell line (such as J774) will confirm whether this variant 
demonstrates greater LUC transcription compared to the non-risk allele. Additional dual-
luciferase reporter assays will be performed in J774 cells transfected with plasmids containing 
different CD-associated SNPs to investigate which SNPs are causal with respect to CD and 
which SNPs are marker CD variants. 
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